Work

MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.7513

Authors: David Jacob Andorsky, Morton Coleman, Abdulraheem Yacoub, Jason M. Melear, Suzanne R. Fanning, Kathryn Kolibaba, Frederick Lansigan, Chris Reynolds, Kenneth A. Foon, Jiahui Li, Mary Llorente, Mathias J. Rummel, Jeff Porter Sharman

Institutions: Rocky Mountain Cancer Centers, Cornell University, Weill Cornell Medicine, The University of Kansas Cancer Center, Texas Oncology, Prisma Health, Compass Oncology, Dartmouth–Hitchcock Medical Center, IHA Hematology Oncology Consultants, Celgene (United States), Justus-Liebig-Universität Gießen, Willamette Valley Cancer Institute and Research Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2954954176

Cites:

Cited by: 17

Related to: 10